Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity

References

• Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet (London, England). 2017;390:946–58. doi:10.1016/S0140-6736(17)30938-8.
   PubMed Web of Science ®Google Scholar
• Amand C, Tong S, Kieffer A, Kyaw MH. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Serv Res. 2018;18:294–294. doi:10.1186/s12913-018-3066-1.
   PubMed Web of Science ®Google Scholar
• Noor A, Krilov LR. Respiratory syncytial virus vaccine: where are we now and what comes next? Expert Opin Biol Ther. 2018;18:1247–56. doi:10.1080/14712598.2018.1544239.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–34. doi:10.1093/oxfordjournals.aje.a120955.
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15:1398–408. doi:10.1016/s1473-3099(15)00247-9.
   PubMed Web of Science ®Google Scholar
• Griffin MP, Khan AA, Esser MT, Jensen K, Takas T, Kankam MK, Villafana T, Dubovsky F. Safety, tolerability, and pharmacokinetics of MEDI8897, the Respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in Healthy adults. Antimicrob Agents Chemother. 2017;61. doi:10.1128/aac.01714-16.
   Web of Science ®Google Scholar
• Ambrose CS, Chen X, Kumar VR. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children. Hum Vaccines Immunother. 2014;10:2785–88. doi:10.4161/hv.32082.
   PubMed Web of Science ®Google Scholar
• Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Carlin D, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J. 1998;17:110–15. doi:10.1097/00006454-199802000-00006.
   PubMed Web of Science ®Google Scholar
• Shepard HM, Phillips GL, Thanos CD, Feldmann M. Developments in therapy with monoclonal antibodies and related proteins. Clin Med (Lond). 2017;17:220–32. doi:10.7861/clinmedicine.17-3-220.
   PubMed Web of Science ®Google Scholar
• Schultheis K, Smith TRF, Ramos S, Schommer N, Jian J, Yung B, Oh J, Yan J, Patel A,  Elliott S. Molecular therapy. p. 269–269. (CAMBRIDGE, MA: CELL PRESS).
   Google Scholar
• McMahon JM, Signori E, Wells KE, Fazio VM, Wells DJ. Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase – increased expression with reduced muscle damage. Gene Ther. 2001;8:1264–70. doi:10.1038/sj.gt.3301522.
   PubMed Web of Science ®Google Scholar
• Elliott STC, Kallewaard NL, Benjamin E, Wachter-Rosati L, McAuliffe JM, Patel A, Smith TRF, Schultheis K, Park DH, Flingai S, et al. DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections. NPJ Vaccines. 2017;2:18. doi:10.1038/s41541-017-0020-x.
   PubMed Web of Science ®Google Scholar
• Patel A, DiGiandomenico A, Keller AE, Smith TRF, Park DH, Ramos S, Schultheis K, Elliott STC, Mendoza J, Broderick KE, et al. An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model. Nat Commun. 2017;8:637. doi:10.1038/s41467-017-00576-7.
   PubMed Web of Science ®Google Scholar
• Wang Y, Esquivel R, Flingai S, Schiller Z A, Kern A, Agarwal S, Chu J, Patel A, Sullivan K, Wise M C, et al. Anti-OspA DNA-encoded monoclonal antibody prevents transmission of spirochetes in tick challenge providing sterilizing immunity in mice. J Infect Dis. 2018. doi:10.1093/infdis/jiy627.
   Web of Science ®Google Scholar
• Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, et al. Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against Chikungunya virus. J Infect Dis. 2016;214:369–78. doi:10.1093/infdis/jiw111.
   PubMed Web of Science ®Google Scholar
• Andrews CD, Luo Y, Sun M, Yu J, Goff AJ, Glass PJ, Padte NN, Huang Y, Ho DD. In vivo production of monoclonal antibodies by gene transfer via electroporation protects against lethal influenza and ebola infections. Mol Ther Methods Clin Dev. 2017;7:74–82. doi:10.1016/j.omtm.2017.09.003.
   PubMed Web of Science ®Google Scholar
• Esquivel RN, Patel A, Kudchodkar SB, Park DH, Stettler K, Beltramello M, Allen JW, Mendoza J, Ramos S, Choi H, et al. In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus. Mol Ther. 2019;27:974–85. doi:10.1016/j.ymthe.2019.03.005.
   PubMed Web of Science ®Google Scholar
• Wise MC, Xu Z, Tello-Ruiz E, Beck C, Trautz, A, Patel A, Elliott ST, Chokkalingam N, Kim S, Kerkau MG, et al. In vivo delivery of synthetic DNA-encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest. 2019. doi:10.1172/JCI132779.
   Web of Science ®Google Scholar
• Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunol Immunother. 2017;66:1577–88. doi:10.1007/s00262-017-2042-7.
   PubMed Web of Science ®Google Scholar
• Hollevoet K, De Smidt E, Geukens N, Declerck P. Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies. Oncotarget. 2018;9:13623–36. doi:10.18632/oncotarget.24426.
   PubMedGoogle Scholar
• Duperret EK, Trautz A, Stoltz R, Patel A, Wise MC, Perales-Puchalt A, Smith T, Broderick KE, Masteller E, Kim JJ, et al. Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo. Cancer Res. 2018;78:6363–70. doi:10.1158/0008-5472.can-18-1429.
   PubMed Web of Science ®Google Scholar
• Hollevoet K, De Vleeschauwer S, De Smidt E, Vermeire G, Geukens N, Declerck P. Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep. Hum Gene Ther. 2019;30:1431–43. doi:10.1089/hum.2019.128.
   PubMed Web of Science ®Google Scholar
• Hollevoet K, Declerck PJ. State of play and clinical prospects of antibody gene transfer. J Transl Med. 2017;15:131–131. doi:10.1186/s12967-017-1234-4.
   PubMed Web of Science ®Google Scholar
• Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, et al. In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model. Cell Rep. 2018;25:1982–1993 e1984. doi:10.1016/j.celrep.2018.10.062.
   PubMed Web of Science ®Google Scholar
• Repp R, Kellner C, Muskulus A, Staudinger M, Mohseni Nodehi S, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PHC, et al. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods. 2011;373:67–78. doi:10.1016/j.jim.2011.08.003.
   PubMed Web of Science ®Google Scholar
• Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. mAbs. 2016;8:120–28. doi:10.1080/19420862.2015.1113360.
   PubMed Web of Science ®Google Scholar
• Boukhvalova MS, Blanco JC. The cotton rat Sigmodon hispidus model of respiratory syncytial virus infection. Curr Top Microbiol Immunol. 2013;372:347–58. doi:10.1007/978-3-642-38919-1_17.
   PubMed Web of Science ®Google Scholar
• Smith TRF, Schultheis K, Morrow MP, Kraynyak KA, McCoy JR, Yim KC, Muthumani K, Humeau L, Weiner DB, Sardesai NY, et al. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine. 2017;35:2840–47. doi:10.1016/j.vaccine.2017.04.008.
   PubMed Web of Science ®Google Scholar
• Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol. 1966;83:299–313. doi:10.1093/oxfordjournals.aje.a120586.
   PubMed Web of Science ®Google Scholar
• Freund C, Ross A, Guth B, Pluckthun A, Holak TA. Characterization of the linker peptide of the single-chain Fv fragment of an antibody by NMR spectroscopy. FEBS Lett. 1993;320:97–100. doi:10.1016/0014-5793(93)80070-b.
   PubMed Web of Science ®Google Scholar
• Haynes AK, Prill MM, Iwane MK, Gerber SI. Respiratory syncytial virus–United States, July 2012-June 2014. MMWR Morb Mortal Wkly Rep. 2014;63:1133–36.
   PubMed Web of Science ®Google Scholar
• Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, Ritter MA. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986;46:6489–93.
   PubMed Web of Science ®Google Scholar
• Prince GA, Capiau C, Deschamps M, Fabry L, Garçon N, Gheysen D, Prieels J-P, Thiry G, Van Opstal O, Porter DD, et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol. 2000;74:10287–92. doi:10.1128/JVI.74.22.10287-10292.2000.
   PubMed Web of Science ®Google Scholar
• Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol. 1986;57:721–28. doi:10.1128/JVI.57.3.721-728.1986.
   PubMed Web of Science ®Google Scholar
• Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharm Sci. 2014;125:125–31. doi:10.1254/jphs.14R02CP.
   PubMed Web of Science ®Google Scholar
• Mir LM, Bureau MF, Rangara R, Schwartz B, Scherman D. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. Comptes rendus l’Acad Sci. 1998;321:893–99. doi:10.1016/s0764-4469(99)80003-1.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Ataka K, Gejyo F, Higuchi N, Ito Y, Hirahara H, Imazeki I, Hirata M, Ichikawa F, Neichi T, et al. Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats. Gene Therapy. 2001;8:461–68. doi:10.1038/sj.gt.3301412.
   PubMed Web of Science ®Google Scholar
• Raghavan P, Lu Y, Mirchandani M, Stecco A. Human recombinant hyaluronidase injections for upper limb muscle stiffness in individuals with cerebral injury: a case series. EBioMedicine. 2016;9:306–13. doi:10.1016/j.ebiom.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory syncytial virus seasonality - United States, 2014–2017. MMWR Morb Mortal Wkly Rep. 2018;67:71–76. doi:10.15585/mmwr.mm6702a4.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother. 2012;56:4927–36. doi:10.1128/aac.06446-11.
   PubMed Web of Science ®Google Scholar
• AlQahtani AD, O’Connor D, Domling A, Goda SK. Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomed Pharmacother. 2019;113:108750. doi:10.1016/j.biopha.2019.108750.
   PubMed Web of Science ®Google Scholar
• Tan H, Su W, Zhang W, Wang P, Sattler M, Zou P. Recent advances in half-life extension strategies for therapeutic peptides and proteins. Curr Pharm Des. 2018;24:4932–46. doi:10.2174/1381612825666190206105232.
   PubMed Web of Science ®Google Scholar
• Zaman R, Islam RA, Ibnat N, Othman I, Zaini A, Lee CY, Chowdhury EH. Current strategies in extending half-lives of therapeutic proteins. J Controlled Release. 2019;301:176–89. doi:10.1016/j.jconrel.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 2009;23:93–109. doi:10.2165/00063030-200923020-00003.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol. 2007;368:652–65. doi:10.1016/j.jmb.2007.02.024.
   PubMed Web of Science ®Google Scholar
• Tiwari PM, Vanover D, Lindsay KE, Bawage SS, Kirschman JL, Bhosle S, Lifland AW, Zurla C, Santangelo PJ. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection. Nat Commun. 2018;9:3999–3999. doi:10.1038/s41467-018-06508-3.
   PubMed Web of Science ®Google Scholar
• Kakuk TJ, Soike K, Brideau RJ, Zaya RM, Cole SL, Zhang J-Y, Roberts ED, Wells PA, Wathen MW. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis. 1993;167:553–61. doi:10.1093/infdis/167.3.553.
   PubMed Web of Science ®Google Scholar
• Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;S1525–0016(1520)30002–30002. doi:10.1016/j.ymthe.2020.01.001.
   Google Scholar
• Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017;8:14630. doi:10.1038/ncomms14630.
   PubMed Web of Science ®Google Scholar
• Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Controlled Release. 2015;217:345–51. doi:10.1016/j.jconrel.2015.08.007.
   PubMed Web of Science ®Google Scholar
• Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, et al. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017;9:1434–47. doi:10.15252/emmm.201707678.
   PubMed Web of Science ®Google Scholar
• Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV. Virology. 2008;378:79–85. doi:10.1016/j.virol.2008.04.016.
   PubMed Web of Science ®Google Scholar
• Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, Knoblock D, Gillespie E, Amante D, Racine T, et al. Intradermal SynCon(R) ebola GP DNA vaccine is temperature stable and safely demonstrates cellular and humoral immunogenicity advantages in healthy volunteers. The Journal of Infectious Diseases. 2019;220:400–10. doi:10.1093/infdis/jiz132.
   PubMed Web of Science ®Google Scholar